October Term 2011 · Docket 10-844

Can a generic drug maker sue a brand-name company over FDA use codes?

Caraco argues the law bars its patent suit. Novo Nordisk claims the statute allows the challenge.

Official caption
Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S
Latest argument session
Latest official Court activity
Latest verified event
Argued
Sources analyzed through
Official Transcript

Verified source milestones

  1. — An official oral-argument transcript was verified.
  2. — An official oral-argument transcript was verified.

The arguments, in order

This case may have been argued more than once. Each entry below uses that session's official transcript. Later arguments do not erase earlier ones.

  1. Argument 1 ·

    What happened at the argument

    Mr. Hurst argued that a statutory path exists for generic drugs since 1984.

    Mr. Perry argued the core issue is an administrative law challenge to the FDA.

    Mr. Horwich discussed the FDA's role in writing use codes for drugs.

    Read the official transcript for this argument · Official argument details

    Sources used for this argument breakdown

A citizen's guide to the whole case

What this case is about

This case tests whether a generic drug maker can sue a brand-name company over FDA use codes. Caraco seeks to dismiss the patent claim. Novo Nordisk wants the court to allow the suit to proceed.

Official sources for this section

How the case got here

The Supreme Court heard oral argument in this case on December 5, 2011.

Official sources for this section

What each side wants

Caraco wants the court to dismiss the patent claim against it.

Novo Nordisk wants the court to allow the patent claim to proceed.

Official sources for this section

What each side says

Caraco argues the statute does not cover this specific FDA use code scenario.

Novo Nordisk argues the statute permits a challenge to the FDA's administration.

Official sources for this section

What the justices asked

Justice Ginsburg asked if the original drug patent had already expired.

Justice Scalia asked if the statute explicitly excludes generic use claims.

Official sources for this section

Why it matters

This dispute determines how generic drug makers challenge brand-name patents. It affects the speed of generic drug entry into the market. It shapes the balance between patent rights and public access to medicine.

Official sources for this section

What happens next

This article currently covers the argument record. Use the official docket link for later case activity.

Official sources for this section

Official Court provenance

Official docket and case history · Official Supreme Court oral-argument detail page

Title and summary sources

Revision history

  1. Revision 1 · Official Transcript ·

    Correction: Rewritten to the concise citizen-facing editorial standard.

  2. Revision 2 · Official Transcript ·

    Correction: Migrated to the dated official Court activity contract without model use.

Download this sanitized case as JSON